Journal: Endoscopy International Open

Article Title: Use of rebamipide solution as a submucosal injection material to prevent esophageal stricture after endoscopic submucosal dissection: Animal study

doi: 10.1055/a-2820-3721

Figure Lengend Snippet: Histopathologic evaluation of ulcer healing. a Thickness of granulation tissue and representative images of Azan-Mallory staining in the rebamipide and control groups on POD 7 (Scale bar, 1000 µm). The rebamipide group exhibited a greater thickness of granulation tissue compared with the control group (718.0 ± 144.0 µm vs. 589.6 ± 84.9 µm), although this difference did not reach statistical significance (P = 0.12). b The number of microvessels and representative images of α-SMA sections in the rebamipide and control groups on POD 7 (Scale bar, 50 µm). Although the rebamipide group showed a greater number of microvessels (17.0 ± 3.4 vs. 13.8 ± 1.5), the difference was not statistically significant (P = 0.10). c Widths of absent muscularis mucosae and representative images of Azan Mallory staining in the rebamipide and control groups on PODs 7, 14 and 21 (Scale bar, 2500 µm for POD 7; 1000 µm for PODs 14 and 21). Mean widths in the rebamipide and control groups on PODs 7, 14, and 21 were 13.8 ± 2.8 ×10³/µm vs. 13.9 ± 2.2 ×10³/µm (P = 0.93), 4.0 ± 1.7 ×10³/µm vs. 5.3 ± 1.9 ×10³/µm (P = 0.33), and 2.3 ± 1.6 ×10³/µm vs. 3.5 ± 2.2 ×10³/µm (P = 0.37), respectively. Although widths tended to be shorter in the rebamipide group on PODs 14 and 21, no statistically significant differences were detected. Linear mixed‑effects analysis revealed no significant group-time interaction. α-SMA, α-smooth muscle actin; POD, postoperative day.

Article Snippet: Serial sections were cut for immunostaining using the mouse monoclonal anti-α-smooth muscle actin (α-SMA) antibody (1:400 dilution, 1A4/asm-1; Novus Biologicals, Littleton, Colorado, United States).

Techniques: Staining, Control

Journal: Endoscopy International Open

Article Title: Use of rebamipide solution as a submucosal injection material to prevent esophageal stricture after endoscopic submucosal dissection: Animal study

doi: 10.1055/a-2820-3721

Figure Lengend Snippet: Histopathologic evaluation of fibrosis formation. a Proportion of α-SMA-positive cells and representative images of α-SMA sections in the rebamipide and control groups on PODs 7, 14, and 21 (Scale bar, 50 µm). Proportions of α‑SMA–positive cells in the rebamipide and control groups on PODs 7, 14, and 21 were 29.0 ± 9.1% vs. 35.1 ± 9.0% (P = 0.22), 24.3 ± 7.9% vs. 27.4 ± 7.5% (P = 0.52), and 19.2 ± 2.2% vs. 25.8 ± 7.4% (P = 0.18), respectively ( a ). Although none of these differences were statistically significant, the rebamipide group consistently showed lower proportions of α‑SMA–positive cells across all time points. Linear mixed‑effects analysis revealed no significant group–time interaction. b Thickness of fibrosis and representative images of Azan-Mallory staining in the rebamipide and control groups on PODs 7, 14, and 21 (Scale bar, 500 µm). Thickness of fibrosis in the rebamipide and control groups on PODs 7, 14, and 21 was 558.6 ± 169.7 µm vs. 450.8 ± 131.1 µm (P = 0.58), 807.0 ± 238.9 µm vs. 972.8 ± 395.1 µm (P = 0.40), and 782.8 ± 281.5 µm vs. 1087.0 ± 476.0 µm (P = 0.13), respectively. Fibrosis progressed on POD 7 but was attenuated on PODs 14 and 21 in the rebamipide group compared with the control group. Linear mixed‑effects analysis demonstrated a significant group–time interaction, with the between‑group difference becoming evident at POD 21 (P = 0.049). α-SMA, α-smooth muscle actin; POD, postoperative day

Article Snippet: Serial sections were cut for immunostaining using the mouse monoclonal anti-α-smooth muscle actin (α-SMA) antibody (1:400 dilution, 1A4/asm-1; Novus Biologicals, Littleton, Colorado, United States).

Techniques: Control, Staining